Login Register
About Us
Invite People

Share 4Engineers with your friends and help them get started!

Emails
Enter multiple email addresses by separating it with a comma.
Advanced Search
Back
4Engineers
· Chemical Engineering Online
AI summary

Lonza will expand HPAPI and ADC payload-linker manufacturing at its Visp site, enhancing its drug-linker center of excellence and adding new commercial-scale capabilities for complex, highly potent ingredients—reinforcing its position as a fully integrated CDMO for antibody-drug conjugates.

What do you think are the biggest hurdles to scaling HPAPI and ADC payload-linker production—occupational safety, supply chain robustness, or regulatory complexity?

Lonza to expand HPAPI manufacturing capacity at Visp site

This article was originally posted on Chemical Engineering.
View article ->

Lonza AG (Basel, Switzerland) announced plans to enhance its drug-linker center of excellence and expand payload-linker manufacturing capacity at its Visp site. The expansion will establish new commercial-scale capabilities for the manufacture of highly complex and highly potent active pharmaceutical ingredients (HPAPI) and ADC payload-linkers, reinforcing Lonza’s position as the leading and fully-integrated contract development […]

The post Lonza to expand HPAPI manufacturing capacity at Visp site appeared first on Chemical Engineering.

Login to comment

Login
Discussion

1 comment
Collapse this comment
pat 1 month ago
Scaling HPAPI is all about containment fidelity; are they going fully closed transfer with alpha-beta RTPs/split-butterfly valves and pressure-cascade suites with hard HVAC interlocks so a fan trip can’t blow OEB5? Are they leaning on single-use where possible to ease cleaning validation between payloads? Also curious how they’re sizing solvent recovery and cytotoxic waste incineration so maintenance or permits don’t bottleneck the plant.

Related Conversations

Recent Conversations

Your Conversations

Report content
Reason Description